Found: 32
Select item for more details and to access through your institution.
Oral Preexposure Prophylaxis Uptake and Discontinuation in the HIV Vaccine Trials Network 704/HIV Prevention Trials Network 085 Study: Implications for Biomedical Human Immunodeficiency Virus Prevention Trials.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 7, p. 1, doi. 10.1093/ofid/ofae387
- By:
- Publication type:
- Article
Sieve analysis of breakthrough HIV-1 sequences in HVTN 505 identifies vaccine pressure targeting the CD4 binding site of Env-gp120.
- Published in:
- PLoS ONE, 2017, v. 12, n. 11, p. 1, doi. 10.1371/journal.pone.0185959
- By:
- Publication type:
- Article
Phase 1 Human Immunodeficiency Virus (HIV) Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Subtype C DNA and MF59-Adjuvanted Subtype C Envelope Protein.
- Published in:
- Clinical Infectious Diseases, 2021, v. 72, n. 1, p. 50, doi. 10.1093/cid/ciz1239
- By:
- Publication type:
- Article
Protein Dose-Sparing Effect of AS01<sub>B</sub> Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 2, p. e405, doi. 10.1093/infdis/jiad434
- By:
- Publication type:
- Article
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention.
- Published in:
- PLoS Computational Biology, 2022, v. 18, n. 4, p. 1, doi. 10.1371/journal.pcbi.1010003
- By:
- Publication type:
- Article
Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.
- Published in:
- Nature, 2012, v. 490, n. 7420, p. 417, doi. 10.1038/nature11519
- By:
- Publication type:
- Article
1272. Feasibility and Successful Enrollment in Proof-of-Concept Trials to Assess Safety and Efficacy of a Broadly Neutralizing Monoclonal Antibody, VRC01, to Prevent HIV-1 Acquisitionin in Uninfected Individuals.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S457, doi. 10.1093/ofid/ofz360.1135
- By:
- Publication type:
- Article
Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial.
- Published in:
- PLoS Computational Biology, 2015, v. 11, n. 2, p. 1, doi. 10.1371/journal.pcbi.1003973
- By:
- Publication type:
- Article
Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0087572
- By:
- Publication type:
- Article
Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial.
- Published in:
- PLoS ONE, 2013, v. 8, n. 1, p. 1, doi. 10.1371/journal.pone.0053629
- By:
- Publication type:
- Article
MRKAd5 HIV-1 Gag/Pol/Nef Vaccine-Induced T-Cell Responses Inadequately Predict Distance of Breakthrough HIV-1 Sequences to the Vaccine or Viral Load.
- Published in:
- PLoS ONE, 2012, v. 7, n. 8, p. 1, doi. 10.1371/journal.pone.0043396
- By:
- Publication type:
- Article
HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 296, p. 1, doi. 10.1126/scitranslmed.aab4005
- By:
- Publication type:
- Article
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination.
- Published in:
- Science Translational Medicine, 2014, v. 6, n. 228, p. 1, doi. 10.1126/scitranslmed.3007730
- By:
- Publication type:
- Article
Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Human adenovirus-specific T cells modulate HIV-specific T cell responses to an Ad5-vectored HIV-1 vaccine.
- Published in:
- Journal of Clinical Investigation, 2012, v. 122, n. 1, p. 359, doi. 10.1172/JCI60202
- By:
- Publication type:
- Article
Author Correction: High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
- Published in:
- 2024
- By:
- Publication type:
- Correction Notice
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features.
- Published in:
- Nature Communications, 2024, v. 15, n. 1, p. 1, doi. 10.1038/s41467-024-46536-w
- By:
- Publication type:
- Article
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
- Published in:
- Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-43384-y
- By:
- Publication type:
- Article
V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144.
- Published in:
- PLoS ONE, 2017, v. 12, n. 7, p. 1, doi. 10.1371/journal.pone.0180720
- By:
- Publication type:
- Article
Peptide Targeted by Human Antibodies Associated with HIV Vaccine-Associated Protection Assumes a Dynamic α-Helical Structure.
- Published in:
- PLoS ONE, 2017, v. 12, n. 1, p. 1, doi. 10.1371/journal.pone.0170530
- By:
- Publication type:
- Article
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
- Published in:
- PLoS Medicine, 2020, v. 17, n. 5, p. 1, doi. 10.1371/journal.pmed.1003117
- By:
- Publication type:
- Article
Antibody and cellular responses to HIV vaccine regimens with DNA plasmid as compared with ALVAC priming: An analysis of two randomized controlled trials.
- Published in:
- 2020
- By:
- Publication type:
- journal article
SieveSifter: a web-based tool for visualizing the sieve analyses of HIV-1 vaccine efficacy trials.
- Published in:
- Bioinformatics, 2017, v. 33, n. 15, p. 2386, doi. 10.1093/bioinformatics/btx168
- By:
- Publication type:
- Article
Human immunoglobulin gene allelic variation impacts germline-targeting vaccine priming.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00811-5
- By:
- Publication type:
- Article
A first-in-human germline-targeting HIV nanoparticle vaccine induced broad and publicly targeted helper T cell responses.
- Published in:
- Science Translational Medicine, 2023, v. 15, n. 697, p. 1, doi. 10.1126/scitranslmed.adf3309
- By:
- Publication type:
- Article
Genetic impact of vaccination on breakthrough HIV-1 sequences from the STEP trial.
- Published in:
- Nature Medicine, 2011, v. 17, n. 3, p. 366, doi. 10.1038/nm.2316
- By:
- Publication type:
- Article
Finite-sample corrected generalized estimating equation of population average treatment effects in stepped wedge cluster randomized trials.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Magnitude and Breadth of a Nonprotective Neutralizing Antibody Response in an Efficacy Trial of a Candidate HIV-1 gpl20 Vaccine.
- Published in:
- Journal of Infectious Diseases, 2010, v. 202, n. 4, p. 595, doi. 10.1086/654816
- By:
- Publication type:
- Article
Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV.
- Published in:
- Pharmaceutics, 2024, v. 16, n. 5, p. 594, doi. 10.3390/pharmaceutics16050594
- By:
- Publication type:
- Article
Histo-Blood Group Antigen Phenotype Determines Susceptibility to Genotype-Specific Rotavirus Infections and Impacts Measures of Rotavirus Vaccine Efficacy.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial.
- Published in:
- 2017
- By:
- Publication type:
- journal article